CAR T-cell therapy for HER2-positive cancers
A novel CAR T-cell therapy targeting the HER2 antigen demonstrated safety and clinical benefit in patients with advanced sarcoma during a Phase 1 clinical trial, as reported on March 16, 2026, by researchers at Baylor College of Medicine and Texas Children's Hospital. As of March 16, 2026: This therapy is showing promise in solid tumors, building on the 2017 FDA approval of Kymriah for acute lymphoblastic leukemia and the first successful clinical application of CAR T-cells in 2010. Another related study reported on a second-generation CAR T-cell therapy targeting p95HER2, which showed safety and complete, durable responses in preclinical models. Ongoing efforts include new CRISPR-based screening methods to enhance CAR T-cell activity and a clinical trial for a different autologous CAR-T for solid tumors (GCAR1) starting January 31, 2026.
Timeline
Want updates on this thread?
Track this story2026
2 updates
2026
2 updatesA novel CAR T-cell therapy targeting the HER2 antigen has demonstrated safety and clinical benefit in patients with advanced sarcoma during a Phase 1 clinical trial. Researchers at Baylor College of Medicine and Texas Children's Hospital are leading this study. Another related study reported on a second-generation CAR T-cell therapy targeting p95HER2, which showed safety and complete, durable responses in preclinical models.
New CRISPR-based screening methods are presented, identifying gene targets that could further enhance CAR T-cell proliferation and anti-tumor activity, indicating ongoing efforts to refine CAR-T technologies.
via en.wikipedia.org·pmc.ncbi.nlm.nih.gov·explorecelltherapy.com·onco-hema.healthbooktimes.org
2025
3 updates
2025
3 updatesA clinical trial for a different CAR-T therapy (GCAR1), an autologous CAR-T for solid tumors, is first posted, with a study start date of January 31, 2026, indicating ongoing clinical translation efforts in CAR-T for solid tumors.
via en.wikipedia.org·pmc.ncbi.nlm.nih.gov·explorecelltherapy.com·onco-hema.healthbooktimes.org
A review article discusses the broader landscape of UCAR-T cell engineering and clinical strategies, noting progress in hematological malignancies but persistent challenges in solid tumors, underscoring the importance of GA1CAR's advancements.
via en.wikipedia.org·pmc.ncbi.nlm.nih.gov·explorecelltherapy.com·onco-hema.healthbooktimes.org
An international Phase 1/2 clinical trial for a new universal CAR-T cell therapy for aggressive T cell cancers showed promising outcomes, including high response and remission rates with manageable toxicity.
via news-medical.net
2021
1 update
2021
1 updateThe concept of Universal CAR-T (UCAR-T) cell therapy gains significant attention as a strategy to overcome the manufacturing and cost limitations of autologous CAR-T.
via en.wikipedia.org·pmc.ncbi.nlm.nih.gov·explorecelltherapy.com·onco-hema.healthbooktimes.org
2017
1 update
2017
1 updateThe U.S. FDA grants approval to Kymriah (tisagenlecleucel), the first CAR T-cell therapy, for acute lymphoblastic leukemia (ALL), marking a major regulatory and clinical breakthrough.
via en.wikipedia.org·pmc.ncbi.nlm.nih.gov·explorecelltherapy.com·onco-hema.healthbooktimes.org
2010
1 update
2010
1 updateThe first successful clinical application of CAR T-cells in a patient with chronic lymphocytic leukemia (CLL) at the University of Pennsylvania achieves complete remission, demonstrating the therapy's potential.
via en.wikipedia.org·pmc.ncbi.nlm.nih.gov·explorecelltherapy.com·onco-hema.healthbooktimes.org
2003
1 update
2003
1 updateDr. Michel Sadelain's group introduces CD19-targeting CAR T cells, a pivotal development that sets the stage for effective CAR T-cell therapies in hematological malignancies.
via en.wikipedia.org·pmc.ncbi.nlm.nih.gov·explorecelltherapy.com·onco-hema.healthbooktimes.org
1993
1 update
1993
1 updateLandmark studies demonstrate the ability to genetically engineer human T cells to recognize and kill cancer, and the first-generation CARs are created, though initial in vivo efficacy is limited.
via en.wikipedia.org·pmc.ncbi.nlm.nih.gov·explorecelltherapy.com·onco-hema.healthbooktimes.org
1987
1 update
1987
1 updateThe foundational concept of chimeric antigen receptors (CARs) is first proposed by researchers, laying the theoretical groundwork for CAR T-cell therapy.
via en.wikipedia.org·pmc.ncbi.nlm.nih.gov·explorecelltherapy.com·onco-hema.healthbooktimes.org
2024
Story began · 1 year, 3 mo ago